ReviewFoundationThe next generation of antimicrobial peptides (AMPs) as molecular therapeutic tools for the treatment of diseases with social and economic impacts

- Review of the present status of the development of antimicrobial peptides (AMPs).
- Recent advances in designing new anti-infective agents with enhanced activity.
- Transient expression of AMPs in tobacco to boost the biosynthesis of pharmaceutics.
- CRISPRs, an impressive genome editing tool to enhance the biosynthesis of new AMPs.

Anti-infective drugs have had a key role in the contemporary world, contributing to dramatically decrease mortality rates caused by infectious diseases worldwide. Antimicrobial peptides (AMPs) are multifunctional effectors of the innate immune system of mucosal surfaces and present antimicrobial activity against a range of pathogenic viruses, bacteria, and fungi. However, the discovery and development of new antibacterial drugs is a crucial step to overcome the great challenge posed by the emergence of antibiotic resistance. In this review, we outline recent advances in the development of novel AMPs with improved antimicrobial activities that were achieved through characteristic structural design. In addition, we describe recent progress made to overcome some of the major limitations that have hindered peptide biosynthesis.